



Whanganui DHB 1 Jan - 31 Dec 2021

% susceptible clinical isolates, screening not included													
	<i>S. aureus</i> (sterile sites)	<i>S. aureus</i> (non-sterile sites)	MRSA	Coagulase negative Staphylococci (blood)	<i>Staph saprophyticus</i> (urine)	<i>Strep. pneumoniae</i> #	<i>Enterococcus</i> spp	<i>Haemophilus influenzae</i>	<i>Pseudomonas aeruginosa</i>	<i>E. coli</i> (blood)	<i>E. coli</i> (urine)	<i>E. coli</i> ESBL (urine)	<i>Klebsiella</i> species
Approx No. Tested	60	1300	150	90	90	50-60#	200	60	220	50	2000	100	150
Amoxicillin			R			97	90	61	R			R	R
Amox/Clav			R					67	R	49	86**		88**
Cefalexin***			R				R		R		93	R	89
Cefepime			R				R		92			R	
Ceftazidime			R				R		94			R	
Ceftriaxone			R			≥97	R	98	R	92		R	91
Cefuroxime			R				R		R	90		R	Insuff
Clindamycin	90	91	84	77									
Cotrimoxazole		98	100		97	76	R	72	R				89
Erythromycin		89	81			92							
Flucloxacillin	95	89	R	55	98		R						
Fluoroquinolones							R		89	89	93	44	89
Fusidic Acid		87	62				R						
Gentamicin										98		82	96
Meropenem			R						95	100		100	100
Nitrofurantoin***					100		98*				99	99	
Penicillin			R			Insuff							
Pip/Taz			R						92	96			89
Tetracycline		96	90			88		100					
Tobramycin									99	98		81	96
Trimethoprim***					96						78	56	90
Vancomycin	100	100	100	100			100						
ESBL+ve -% of total										8%	3%		2%
AmpC+ve -% of total										4%	2%		2%
Carbapenemase+ve % of total									0%	0%	0%		0%

≥ 90% of isolates susceptible
 70 - 90% of isolates susceptible
 Insuff Insufficient isolates (<30)

< 70% of isolates susceptible
 R Intrinsically Resistant

Isolates reported as "Susceptible, increased exposure" are now regarded as part of the Susceptible group.

Isolates for 2020 and 2021 included to reach >30 isolates

* *Enterococcus faecalis* only, no breakpoints available for *Enterococcus faecium*

** Refers to uncomplicated UTI